|

PF-06821497 Clinical Trials

1 actively recruiting trial across 1 location

▼ -1 trial since May 2026

Also known as: Mevrometostat

Pipeline

Phase 3: 1

Top Sponsors

  • Pfizer1

Indications

  • Metastatic Castration-resistant Prostate Cancer1
  • Cancer1

Chandler, Arizona1 trial

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Ironwood Cancer & Research Centers

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.